These results serve as a rationale for ONC201 single - agent trials in relapsed / refractory acute leukemia, non-Hodgkin's lymphoma, MM and combination trial with dexamethasone in MM,
provide pharmacodynamic biomarkers and identify further synergistic combinatorial regimens that can be explored in the clinic.